ENTITY
Innovent Biologics Inc

Innovent Biologics Inc (1801 HK)

364
Analysis
Health CareChina
Innovent Biologics, Inc. operates as a biopharmaceutical company. The Company develops, manufactures, and distributes monoclonal antibody drug candidates for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and other diseases. Innovent Biologics serves customers in China.
more
Refresh
18 May 2020 15:32

Legend Biotech IPO Initiation: Choosing Therapies À La CAR-T

Legend Biotech (BLG US) is one of the leading companies in developing CAR-T cell therapies in China, having received clearance for the first CAR-T...

Logo
148 Views
Share
11 May 2020 14:25

Short Interest Spiked for China Gas, Country Garden Svc, Big Covers for Innovent

Hong Kong SFC reported today for aggregate short position on Apr 29. The aggregate short value for equities increased by $1,489m (+2.7%) WoW and...

Logo
235 Views
Share
23 Apr 2020 12:35

Akesobio: Trading Debut, Valuation Scenario Analysis

Akeso Biopharma Inc (9926 HK) is a clinical-stage biopharmaceutical company with aims to address global unmet medical needs in oncology, immunology...

Logo
466 Views
Share
14 Apr 2020 14:04

Akesobio IPO: Valuation Insights

Akeso Biopharma Inc (9926 HK) is a clinical-stage biopharmaceutical company with aims to address global unmet medical needs in oncology, immunology...

Logo
474 Views
Share
08 Apr 2020 19:50

Akesobio IPO Initiation: The Tough Get Going

Akeso Biopharma Inc (1495016D CH) is a clinical-stage biopharmaceutical company with aims to address global unmet medical needs in oncology,...

Logo
462 Views
Share
x